Topcon Europe invests in LensAR

October 12, 2011

Topcon Europe Medical BV has made an equity investment in LensAR, creating a long-term strategic cooperation that includes distribution and marketing of LensAR’s proprietary laser system in Europe.

Rotterdam, Netherlands, and Orlando-Topcon Europe Medical BV has made an equity investment in LensAR, creating a long-term strategic cooperation that includes distribution and marketing of LensAR’s proprietary laser system in Europe.

LensAR is a developer of a next-generation laser (LensAR Laser System) and 3-D imaging technology for refractive cataract surgery. The system is cleared by the FDA for anterior capsulotomy and lens fragmentation; for other indications, it is an investigational device in the United States.

“This is a very exciting opportunity for Topcon to demonstrate our commitment to technologies that will have a positive and significant impact on enhancing patient outcomes that are synergistic with our portfolio of products in ocular surgery, implants, and diagnostics,” said Eric Franken, managing director, Topcon Europe Medical BV. “This latest announcement shows our commitment and confidence in the [laser system] to expand our offering to our partner, the ophthalmic surgeon, and help us continue to combine our quality diagnostics with the newest surgical technologies.”

For more articles in this issue of Ophthalmology Times eReport, click here.